From the Journals

Frequent cannabis use in depression tripled over past decade


 

Not only are individuals with depression at significantly higher risk for cannabis use, compared with those without depression, this trend has increased dramatically over the last decade, new research shows.

Investigators analyzed data from more than 16,000 U.S. adults between the ages of 20 and 59 years and found that those with depression had almost twice the odds of any past-month cannabis use compared with those without depression. Odds rose from 1.5 in the 2005-2006 period to 2.3 in the 2015-2016 period.

Moreover, the odds ratio for daily or near-daily use almost tripled for those with versus without depression between the two periods.

Dr. Deborah Hasin

“Clinicians should screen their depressed patients for cannabis use, since this is becoming more common and could actually make their depressive symptoms worse rather than better,” senior author Deborah Hasin, PhD, professor of epidemiology, Columbia University Irving Medical Center, New York City, told Medscape Medical News.

The results were published online August 18 in JAMA Network Open.

Misleading advertising

“Cannabis use is increasing in the U.S. and the potency of cannabis products is increasing as well,” Dr. Hasin said.

“Misleading media information and advertising suggests that cannabis is a good treatment for depression, although studies show that cannabis use may actually worsen depression symptoms, [so] we were interested in whether U.S. adults were increasingly likely to be cannabis users if they were depressed,” she reported.

To investigate, the researchers assessed data from the National Health and Nutrition Examination Survey (NHANES), with a final study sample consisting of 16,216 U.S. adults. The mean age was 39.12 years, 48.9% were men, 66.4% were non-Hispanic White, 65.6% had at least some college education, and 62.4% had an annual family income of less than $75,000.

Of these participants, 7.5% had “probable depression,” based on the Patient Health Questionnaire–9, the investigators report.

Past-month cannabis use was defined as using cannabis at least once during the past 20 days. Daily or near-daily past-month use was defined as using cannabis at least 20 times in the past 30 days.

Covariates included age, gender, race, education, marital status, annual family income, and past-year use of other substances, such as alcohol, heroin, and methamphetamine.

The researchers note that because the NHANES data were divided into six survey years (2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, and 2015-2016), their analysis was based on a “new sample weight” that combined the datasets.

Especially pronounced

Results showed that the prevalence of any past-month cannabis use in the overall sample group increased from 12.2% in the 2005-2006 period to 17.3% in the 2015-2016 period (P < .001).

The investigators characterized this change as “significant,” adding that the estimated odds of cannabis use increased by approximately 9% between every 2-year time period.

The change was even more dramatic when the increase was examined across survey time periods (OR, 1.12; P < .001). The estimated odds of daily or near-daily use increased by approximately 12% between every 2-year period.

Interestingly, however, there were no significant changes in odds for depression when consecutive survey years were compared.

When the researchers specifically focused on the association between any past-month cannabis use and depression versus no depression, they found an adjusted OR of 1.90 (95% CI, 1.62-2.12; P < .001).

Individuals with depression also had 2.29 (95% CI, 1.80-2.92) times the odds for daily or near-daily cannabis use, compared with those without depression.

A post-hoc analysis looked at time trends in a sample group that included those missing information on at least one covariate (n = 17,724 participants). It showed similar results to those in the final sample that included no missing data.

People with depression have increased risk of using “most substances that can be abused,” Dr. Hasin said. “However, with the overall rates of cannabis use increasing in the general population, this is becoming especially pronounced for cannabis.”

Pages

Recommended Reading

FDA okays new indication for esketamine nasal spray
MDedge Psychiatry
A doctor conquers his demons
MDedge Psychiatry
Exploring cannabis use by older adults
MDedge Psychiatry
ED visits for mental health, substance use doubled in 1 decade
MDedge Psychiatry
Vitamin D fails to prevent late-life depression, boost mood
MDedge Psychiatry
Botulinum toxin associated with antidepressant effects across indications, injection sites
MDedge Psychiatry
Chloroquine linked to serious psychiatric side effects
MDedge Psychiatry
CDC data confirm mental health is suffering during COVID-19
MDedge Psychiatry
Anxiety disorders begin earlier in life, differ by gender
MDedge Psychiatry
The transitions of COVID-19
MDedge Psychiatry